DK3102218T3 - Behandling af topiske og systemiske bakterieinfektioner - Google Patents
Behandling af topiske og systemiske bakterieinfektioner Download PDFInfo
- Publication number
- DK3102218T3 DK3102218T3 DK15703086.7T DK15703086T DK3102218T3 DK 3102218 T3 DK3102218 T3 DK 3102218T3 DK 15703086 T DK15703086 T DK 15703086T DK 3102218 T3 DK3102218 T3 DK 3102218T3
- Authority
- DK
- Denmark
- Prior art keywords
- topic
- treatment
- bacteria infections
- systemic
- systemic bacteria
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1402139.8A GB201402139D0 (en) | 2014-02-07 | 2014-02-07 | Treatment of topical and systemic bacterial infections |
PCT/EP2015/052635 WO2015118150A2 (en) | 2014-02-07 | 2015-02-09 | Treatment of topical and systemic bacterial infections |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3102218T3 true DK3102218T3 (da) | 2020-12-07 |
Family
ID=50390631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15703086.7T DK3102218T3 (da) | 2014-02-07 | 2015-02-09 | Behandling af topiske og systemiske bakterieinfektioner |
Country Status (11)
Country | Link |
---|---|
US (4) | US20170020937A1 (da) |
EP (1) | EP3102218B1 (da) |
JP (1) | JP6736476B6 (da) |
CN (1) | CN106132440A (da) |
AU (1) | AU2015214135B2 (da) |
CA (1) | CA2937607C (da) |
DK (1) | DK3102218T3 (da) |
ES (1) | ES2835707T3 (da) |
GB (1) | GB201402139D0 (da) |
PT (1) | PT3102218T (da) |
WO (1) | WO2015118150A2 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170157186A1 (en) * | 2015-12-02 | 2017-06-08 | Smart Phage, Inc. | Phage to treat bacteria on skin |
EP3612200A4 (en) * | 2017-04-21 | 2020-12-30 | Phi Therapeutics, Inc. | COMPOSITIONS CONTAINING BACTERIOPHAGES OF PROPIONIBACTERIUM ACNES INTENDED FOR THE TREATMENT OF ACNE |
KR20200102433A (ko) * | 2017-12-05 | 2020-08-31 | 바이오엠엑스 리미티드 | 여드름 및 생물막에 대한 박테리오파지 치료 |
EP3852774A4 (en) | 2018-06-29 | 2022-03-23 | Tets, Viktor, Veniaminovich | METHODS OF DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES |
AU2022272135A1 (en) | 2021-05-12 | 2024-01-04 | Biomx Ltd. | Staphylococcus bacteriophage and uses thereof |
CN116159039A (zh) * | 2023-02-21 | 2023-05-26 | 河北工业大学 | 一种破坏生物膜的近红外光响应共轭聚合物/噬菌体复合纳米粒子 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8918983D0 (en) | 1989-08-21 | 1989-10-04 | Unilever Plc | Composition for hygiene purposes |
US20020001590A1 (en) * | 2000-04-20 | 2002-01-03 | Mount Sinai Hospital | Antibacterial therapy for multi-drug resistant bacteria |
GB0207021D0 (en) | 2002-03-25 | 2002-05-08 | Univ Warwick | Anti-bacterial agents |
JP2005520545A (ja) | 2002-03-25 | 2005-07-14 | ザ ユニバーシティ オブ ワーウィック | 抗細菌剤 |
GB0209680D0 (en) * | 2002-04-27 | 2002-06-05 | Univ Strathclyde | Immobilisation and stabilisation of bacteriophage |
MX2007005279A (es) * | 2004-11-02 | 2008-03-11 | Gangagen Life Sciences Inc | Composiciones de bacteriofagos. |
US20100291537A1 (en) * | 2004-11-16 | 2010-11-18 | Glauco Souza | Methods and compositions related to phage-nanoparticle assemblies |
AU2006268420B2 (en) | 2005-07-12 | 2012-06-28 | Micreos B.V. | Bacteriophage and their uses |
GB0526176D0 (en) * | 2005-12-22 | 2006-02-01 | Blaze Venture Technologies Ltd | Particle binding |
WO2009108964A2 (en) * | 2008-02-28 | 2009-09-03 | Becker Leslie | "zee" developmental plaything |
GB201110647D0 (en) * | 2011-06-23 | 2011-08-10 | Fixed Phage Ltd | Delivery of viral agents |
GB201217097D0 (en) | 2012-09-25 | 2012-11-07 | Fixed Phage Ltd | Treatment of bacterial infection |
-
2014
- 2014-02-07 GB GBGB1402139.8A patent/GB201402139D0/en not_active Ceased
-
2015
- 2015-02-09 PT PT157030867T patent/PT3102218T/pt unknown
- 2015-02-09 EP EP15703086.7A patent/EP3102218B1/en active Active
- 2015-02-09 WO PCT/EP2015/052635 patent/WO2015118150A2/en active Application Filing
- 2015-02-09 US US15/117,076 patent/US20170020937A1/en not_active Abandoned
- 2015-02-09 JP JP2016568124A patent/JP6736476B6/ja active Active
- 2015-02-09 ES ES15703086T patent/ES2835707T3/es active Active
- 2015-02-09 CA CA2937607A patent/CA2937607C/en active Active
- 2015-02-09 DK DK15703086.7T patent/DK3102218T3/da active
- 2015-02-09 CN CN201580018293.9A patent/CN106132440A/zh active Pending
- 2015-02-09 AU AU2015214135A patent/AU2015214135B2/en active Active
-
2019
- 2019-08-05 US US16/532,137 patent/US20190350991A1/en not_active Abandoned
-
2020
- 2020-10-13 US US16/949,091 patent/US20210038658A1/en not_active Abandoned
-
2021
- 2021-06-10 US US17/303,926 patent/US11779618B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN106132440A (zh) | 2016-11-16 |
AU2015214135B2 (en) | 2020-07-23 |
JP6736476B2 (ja) | 2020-08-05 |
US20210038658A1 (en) | 2021-02-11 |
US20190350991A1 (en) | 2019-11-21 |
WO2015118150A3 (en) | 2015-11-12 |
AU2015214135A1 (en) | 2016-08-04 |
US11779618B2 (en) | 2023-10-10 |
GB201402139D0 (en) | 2014-03-26 |
EP3102218A2 (en) | 2016-12-14 |
EP3102218B1 (en) | 2020-09-09 |
ES2835707T3 (es) | 2021-06-23 |
US20210290703A1 (en) | 2021-09-23 |
CA2937607A1 (en) | 2015-08-13 |
JP6736476B6 (ja) | 2020-12-16 |
JP2017505820A (ja) | 2017-02-23 |
US20170020937A1 (en) | 2017-01-26 |
WO2015118150A2 (en) | 2015-08-13 |
CA2937607C (en) | 2023-08-01 |
PT3102218T (pt) | 2020-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3291679T3 (da) | Ændring af mikrobielle populationer og modificering af mikrobiota | |
DK3129018T3 (da) | Behandling af NAFLD og NASH | |
DK3117310T3 (da) | Håndtering af behandling associeret med valgte arkitektoniske indretninger | |
DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
DK3172213T3 (da) | Makrocykliske kinasehæmmere og anvendelser deraf | |
BR112018000129A2 (pt) | oxiesteróis e seus métodos de utilização | |
GB2554629B (en) | Prevention and treatment of microbial infections | |
DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
DK3155024T3 (da) | Opholdsstrukturer og relaterede fremgangsmåder | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
SG11201609652RA (en) | Treatment of polybacterials infections | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
DK3576738T3 (da) | Gaboxadolmonohydrat i behandling af tinnitus | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
DK3102218T3 (da) | Behandling af topiske og systemiske bakterieinfektioner | |
DK3110447T3 (da) | Anti-EGFR-antistof og anvendelser heraf | |
DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
DK3231793T3 (da) | Dihydropyromidin-2-on-forbindelser og medicinske anvendelser deraf | |
DK3131920T3 (da) | Msp-nanoporer og anvendelser deraf | |
DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
DK3484599T3 (da) | Oprensningsfremgangsmåde og anvendelser deraf | |
DK3285787T3 (da) | Behandling af bakterieinfektioner i akvakultur | |
DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
DK3337506T3 (da) | Kombinationer og anvendelser deraf |